Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Final Analysis of the Phase 2 ROSEWOOD Study

Pier Luigi Zinzani, David Šálek, Christopher R. Flowers, Fontanet Bijou, Ana C. De Oliveira, Yuqin Song, Qingyuan Zhang, Marco Brociner, Krimo Bouabdallah, Peter Ganly, Huilai Zhang, Sam Yuen, Roderick Johnson, Marek Trněný, Rebecca Auer, Alejandro Martín García-Sancho, Mariano Provencio Pulla, Sha Huang, Jiayi Shen, Jamie Hirata, Judith Trotman

Open source

DOI: 10.1007/s11523-026-01268-3
Published: 2026-11-03
Container: Targeted Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s11523-026-01268-3,
  title = {Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Final Analysis of the Phase 2 ROSEWOOD Study},
  author = {Pier Luigi Zinzani and David Šálek and Christopher R. Flowers and Fontanet Bijou and Ana C. De Oliveira and Yuqin Song and Qingyuan Zhang and Marco Brociner and Krimo Bouabdallah and Peter Ganly and Huilai Zhang and Sam Yuen and Roderick Johnson and Marek Trněný and Rebecca Auer and Alejandro Martín García-Sancho and Mariano Provencio Pulla and Sha Huang and Jiayi Shen and Jamie Hirata and Judith Trotman},
  year = {2026},
  journal = {Targeted Oncology},
  doi = {10.1007/s11523-026-01268-3},
  url = {https://doi.org/10.1007/s11523-026-01268-3}
}

RIS

TY  - JOUR
TI  - Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Final Analysis of the Phase 2 ROSEWOOD Study
AU  - Pier Luigi Zinzani
AU  - David Šálek
AU  - Christopher R. Flowers
AU  - Fontanet Bijou
AU  - Ana C. De Oliveira
AU  - Yuqin Song
AU  - Qingyuan Zhang
AU  - Marco Brociner
AU  - Krimo Bouabdallah
AU  - Peter Ganly
AU  - Huilai Zhang
AU  - Sam Yuen
AU  - Roderick Johnson
AU  - Marek Trněný
AU  - Rebecca Auer
AU  - Alejandro Martín García-Sancho
AU  - Mariano Provencio Pulla
AU  - Sha Huang
AU  - Jiayi Shen
AU  - Jamie Hirata
AU  - Judith Trotman
PY  - 2026
JO  - Targeted Oncology
DO  - 10.1007/s11523-026-01268-3
UR  - https://doi.org/10.1007/s11523-026-01268-3
ER  -

APA

Zinzani, P. L., Šálek, D., Flowers, C. R., Bijou, F., Oliveira, A. C. D., Song, Y., Zhang, Q., Brociner, M., Bouabdallah, K., Ganly, P., Zhang, H., Yuen, S., Johnson, R., Trněný, M., Auer, R., García-Sancho, A. M., Pulla, M. P., Huang, S., Shen, J., Hirata, J., & Trotman, J. (2026). Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Final Analysis of the Phase 2 ROSEWOOD Study. Targeted Oncology. https://doi.org/10.1007/s11523-026-01268-3

Source records

crossref · retrieved 2026-11-05T05:35:44.227Z